Infectious Diseases
Conditions
Keywords
Biobank, Bacterial, viral and fungal diseases
Brief summary
The aim of the INFECTIOTEK biobank will be to prospectively build a biobank of multiple biological samples from patients with infectious diseases in order to identify diagnostic and prognostic biomarkers, genetic susceptibility factors and immune response mechanisms in such diseases. The population of the study will consist of patients treated in the Infectious Diseases Departments of Saint-Louis and Lariboisière Hospitals, with a diagnosis of infectious disease, and who have biological samples in the context of their routine medical care. The diseases studied in this research project are bacterial infections (urinary tract infections, neurologic infections, sexually transmitted infections, pulmonary infections), viral infections (HIV, hepatitis, respiratory viruses, viruses affecting immunocompromised patients) and fungal infections (Aspergillus, Mucorales, Cryptococcus). These diseases are the domains of expertise and research of the clinical and biological teams at the Saint-Louis and Lariboisière hospitals.
Interventions
OTHERSampling
Additional biological sampling at the same time as routine-care samples taken in the context of the diagnosis of the infectious disease and if planned at one and 12 months of follow-up * The considered samples are as follows : * Blood sample tubes (5 x 5 mL tubes, i.e. 25 mL) * Infection site sample if applicable : * Urine (10 mL) * Stool (1 mL) * CSF (1 mL) * Sputum (1 mL) or bronchoalveolar lavage fluid (10 mL) * Nasopharyngeal swab (one swab) * Genital swab (one swab) * Skin swab (one swab) * Biopsy (a fragment of a lung, kidney or brain biopsy, if performed)
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient over 18 years of age * Diagnosed with one of the following infectious diseases : * Infection with HIV-1 or HIV-2, or person at risk of infection with HIV * Viral hepatitis (HAV, HBV, HCV, HDV, HEV) * Pulmonary infections: bacterial (notably Nocardia), viral (Influenza, RSV, SARS-CoV-2, Adenovirus), fungal (Aspergillus, Mucorales) * Urinary tract infections * Sexually transmitted infections (Neisseria gonorrheae, Chlamydia trachomatis, Mycoplasma genitalium, Treponema pallidum) * Neuromeningeal infections: (Neisseria meningitidis, Streptococcus pneumoniae), viral (HSV, VZV), fungal (Cryptococcus). * Infections affecting immunocompromised patients: herpes viruses (HSV, VZV, CMV, EBV), polyomavirus BK * Emerging pathogen X (in the event of an epidemic) * Signature of research consent form * Health coverage with social security system or state medical aid
Exclusion criteria
* Refusal to participate * Inability to give consent (cognitive impairment etc...)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic performances of new biomarkers to identify infection | At diagnosis | Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, Positive Likelihood Ratio, Negative Likelihood Ratio of the new biomarker |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Description of pathophysiological phenomena | Until 12 months | Resistance mechanisms, virulence parameters, immune responses to the infectious agent, susceptibility factors to infections |
| Description of prognostic biomarkers | Until 12 months | — |
Contacts
Primary ContactEmma Rubenstein, MD
Backup ContactJérôme Lambert, MD PhD
Outcome results
None listed